Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL‐23, in Patients with Moderate to Severe Plaque Psoriasis

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of clinical pharmacology

• Publication date

  2018-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jcph.1063PMID 29341192
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Baseline

  2020cited by this paper
• Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients

  2017cited by this paper
• Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double‐blind, placebo‐ and active comparator–controlled VOYA

  2017cited by this paper
• Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial

  2017cited by this paper
• First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis

  2016cited by this paper
• Monoclonal Antibody Pharmacokinetics in Type 2 Diabetes Mellitus and Diabetic Nephropathy

  2016cited by this paper
• Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease

  2015cited by this paper
• A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

  2015cited by this paper
• New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors

  2015cited by this paper
• IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases

  2015cited by this paper
• Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint

  2014cited by this paper
• Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR(+) ILC3 in lesional skin and blood of psoriasis patients.

  2014cited by this paper
• Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.

  2014cited by this paper
• The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses.

  2013cited by this paper
• Confirmatory analysis for phase III population pharmacokinetics

  2011cited by this paper
• Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

  2010cited by this paper
• Cytokine Requirements for the Differentiation and Expansion of IL-17A– and IL-22–Producing Human Vγ2Vδ2 T Cells

  2010cited by this paper
• IL-23 Drives Pathogenic IL-17-Producing CD8+ T Cells1

  2009cited by this paper
• Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL‐12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

  2009cited by this paper
• An Improved Approach for Confirmatory Phase III Population Pharmacokinetic Analysis

  2008cited by this paper
• Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells.

  2008cited by this paper
• Psoriasis: epidemiology, clinical features, and quality of life

  2005cited by this paper
• Efficient Screening of Covariates in Population Models Using Wald's Approximation to the Likelihood Ratio Test

  2001cited by this paper
• Ways to Fit a PK Model with Some Data Below the Quantification Limit

  2001cited by this paper
• Glycation increases the vascular clearance rate of IgG in mice

  1993cited by this paper

• A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single‐Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers

  2026cites this paper
• An evaluation of guselkumab for the treatment of ulcerative colitis

  2025cites this paper
• Authors' Reply to: Iqbal J, Ahmad A, and Iltaf A. "Letter to the Editor: Genetic and Pharmacokinetic Considerations in Guselkumab Treatment for Ulcerative Colitis in East Asian Patients".

  2025cites this paper
• Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials

  2025cites this paper
• GUSELKUMAB AS A NEW BIOLOGIC OPTION FOR THE MANAGEMENT OF ULCERATIVE COLITIS: A NARRATIVE REVIEW

  2025cites this paper
• Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis

  2024influential citation
• Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy

  2024cites this paper
• Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis

  2024cites this paper
• Exposure–response relationship of guselkumab and the potential of serum proteomics in identifying predictive biomarker candidates in psoriasis

  2024cites this paper
• Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities

  2024cites this paper
• Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions

  2024cites this paper
• Targeting IL-12 family cytokines: A potential strategy for type 1 and type 2 diabetes mellitus.

  2023cites this paper
• Guselkumab, a Novel Monoclonal Antibody Inhibitor of the p19 Subunit of IL-23, for Psoriatic Arthritis and Plaque Psoriasis: A Review of Its Mechanism, Use, and Clinical Effectiveness

  2023cites this paper
• Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial

  2023cites this paper
• Evaluation of Truncated AUC as an Alternative Measure to Assess Pharmacokinetic Comparability in Bridging Biologic–Device Using Prefilled Syringes and Autoinjectors

  2023cites this paper
• The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry

  2023cites this paper
• Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis

  2023cites this paper
• Prospects for the use of monoclonal antibodies to interleukin 23 Gusеlkumab in psoriatic arthritis: New data

  2022cites this paper
• Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis

  2022influential citation
• Minimal Physiologically-Based Pharmacokinetic (mPBPK) Metamodeling of Target Engagement in Skin Informs Anti-IL17A Drug Development in Psoriasis

  2022cites this paper
• Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis

  2022cites this paper
• Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice

  2021cites this paper
• Interleukin 23 Inhibitors

  2021cites this paper
• Guselkumab in psoriatic arthritis: a profile of its use

  2021cites this paper
• Pharmacokinetic/Pharmacodynamic Analysis of Guselkumab for Treatment of Palmoplantar Pustulosis: Clinical Implications of Guselkumab Dose, Disease Severity, and Smoking in Japanese Patients

  2021cites this paper
• A non-clinical comparative study of IL-23 antibodies in psoriasis

  2021cites this paper
• Effectiveness and safety of guselkumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

  2021cites this paper
• Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis

  2021cites this paper
• The biological basis of disease recurrence in psoriasis: a historical perspective and current models

  2021cites this paper
• Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications

  2020cites this paper
• Evaluating Potential Disease‐Mediated Protein‐Drug Interactions in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab

  2020cites this paper
• Population Pharmacokinetics and Exposure‐Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis

  2020cites this paper
• Pharmacometric Analysis of IgPro10 in Japanese and Non-Japanese Patients With Primary Immunodeficiency.

  2020cites this paper
• Applying Beta Distribution in Analyzing Bounded Outcome Score Data

  2020cites this paper
• Deciphering the Association Between Psoriasis and Obesity: Current Evidence and Treatment Considerations

  2020cites this paper
• Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins for Plaque Psoriasis - Guselkumab

  2019cites this paper
• Guselkumab for the treatment of adults with moderate to severe plaque psoriasis

  2019cites this paper
• The pharmacological management of patients with comorbid psoriasis and obesity

  2019cites this paper
• Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans

  2019cites this paper
• Guselkumab for the treatment of psoriasis – evidence to date

  2019cites this paper
• Use of dose–exposure–response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis

  2019cites this paper
• Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials

  2019cites this paper
• Mechanism and Physiologically Based PK/PD Model in Assisting Translation from Preclinical to Clinical: Understanding PK/PD of Therapeutic Proteins at Site-of-Action

  2019cites this paper
• Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia

  2018cites this paper
• Population Pharmacokinetics and Exposure‐Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis

  2018cites this paper
• Guselkumab: A Review in Moderate to Severe Plaque Psoriasis

  2018cites this paper
• Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials

  2018cites this paper
• A safety evaluation of guselkumab for the treatment of psoriasis

  2018cites this paper
• A comprehensive evaluation of exposure–response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis

  2018cites this paper